2 型糖尿病市场规模、份额和成长分析：按药物类别、给药途径、分销管道、最终用户和地区划分 - 产业预测，2024-2031 年

2022年全球2型糖尿病市场规模估值为340.7亿美元，从2023年的368.7亿美元增至2031年的665.2亿美元，在预测期内（2024-2031年）预计复合年增长率为7.72% 。

据 NCBI 称，全球糖尿病治疗市场预计将从 2014 年的 8,900 万例增至 3.3 亿例，强劲成长主要是由 2 型糖尿病 (T2D) 激增推动。这种激增推动了医学的进步，以创新疗法的推出为代表，例如Glucagon-Like Peptide-1受体促效剂Tanzeum和Trulicity，以及Na-葡萄糖共同输送体2抑制剂Jardiance。儘管取得了这些进步，但由于患者对现有治疗方法的认识较低，市场成长仍面临挑战。相反，在迫切需要有效的糖尿病管理解决方案的发展中地区存在着巨大的机会。糖尿病盛行率的不断上升进一步刺激了对更全面治疗方案的需求，从而导致技术进步，从而实现更具适应性的医疗解决方案。云端基础的企业系统的兴起以及连接设备和应用程式的普及是推动市场扩张的关键趋势。然而，设备高成本、低收入国家资金筹措不足以及对传统糖尿病管理技术的持续依赖等阻碍因素可能会阻碍该行业在预测期内的成长。总体而言，随着医学的不断发展，技术和创新药物疗法的整合对于满足全球糖尿病治疗日益增长的需求至关重要。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 技术分析
• 监管环境
• 专利分析
• PESTEL分析
• 管道分析
• 价格分析

2 型糖尿病市场：依药物类别

• 市场概况
• Dipeptidyl Peptidase-4抑制剂
• 类升糖素胜肽1受体促效剂
• 双胍
• 钠-葡萄糖共同输送体2 (SGLT2) 抑制剂
• 其他的

2 型糖尿病市场：依给药途径

• 市场概况
• 口服
• 胃肠外的

2 型糖尿病市场：按分销管道

• 市场概况
• 医院药房
• 零售药房
• 网路药房

2 型糖尿病市场：依最终用户分类

• 市场概况
• 居家医疗
• 医院/诊所
• 学术/研究机构
• 其他的

2 型糖尿病市场规模：依地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Medtronic
• B. Braun Melsungen AG
• Abbott Laboratories
• F. Hoffmann-La Roche
• Insulet Corporation

Global Type 2 Diabetes Market size was valued at USD 34.07 billion in 2022 and is poised to grow from USD 36.87 billion in 2023 to USD 66.52 billion by 2031, growing at a CAGR of 7.72% during the forecast period (2024-2031).

The global diabetes care market is experiencing robust growth, primarily driven by the alarming rise in type 2 diabetes (T2D) cases, which soared from 89 million in 2014 to an anticipated 330 million by 2022, according to NCBI. This surge has motivated pharmaceutical advances, exemplified by the introduction of innovative therapies such as glucagon-like peptide-1 receptor agonists Tanzeum and Trulicity, as well as the sodium glucose cotransporter 2 inhibitor Jardiance. Despite these advancements, market growth faces challenges due to low patient awareness surrounding available treatments. Conversely, substantial opportunities are projected in developing regions where there is a pressing need for effective diabetes management solutions. The increasing prevalence of diabetes has further intensified the demand for enhanced care options, leading to technological progress that allows for more adaptable healthcare solutions. The rise of cloud-based enterprise systems and the popularity of connected devices and apps are pivotal trends driving market expansion. However, impediments such as the high cost of devices, inadequate funding in lower-income nations, and the continued reliance on traditional diabetes management methods may hinder growth in this sector throughout the forecast period. Overall, as healthcare continues to evolve, the integration of technology and innovative drug therapies will be essential in meeting the escalating demand for diabetes care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the global type 2 diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global type 2 diabetes Market Segmental Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the global type 2 diabetes Market

The rapid advancement of artificial intelligence (AI) is emerging as a significant market driver for the global type 2 diabetes market, revolutionizing the diagnosis and management of this chronic condition. AI's ability to analyze vast amounts of health data through machine learning algorithms enables the development of predictive models that assess individual risk of developing diabetes and its complications. This shift towards precision medicine fosters more personalized and effective treatment strategies, replacing traditional management techniques with data-driven approaches. As healthcare systems increasingly adopt these AI-enhanced solutions, the demand for innovative products and services in the type 2 diabetes space is expected to surge, fueling market growth.

Restraints in the global type 2 diabetes Market

The global type 2 diabetes market faces significant restraint from the lack of reimbursement systems in underdeveloped nations, which often leads to treatment non-compliance among patients. In countries like China and India, individuals are burdened with out-of-pocket expenses for essential diabetes management tools such as continuous glucose monitoring (CGM) systems, insulin, and blood glucose monitors. This financial strain limits access to integrated digital diabetes management solutions, subsequently hindering their widespread adoption in these regions. As the disparity in healthcare funding persists, the growth potential of the type 2 diabetes market in emerging economies may be stifled, affecting overall market expansion.

Market Trends of the global type 2 diabetes Market

The global type 2 diabetes market is increasingly trending towards personalized medicine, driven by advancements in digital health technologies and genetic testing. This customized approach tailors treatment plans to the individual characteristics of patients-including their genetic makeup, lifestyle factors, and comorbidities-aiming to optimize therapeutic outcomes. As healthcare providers recognize the importance of personalized solutions, there is a growing emphasis on enhancing patient adherence and minimizing side effects. This shift not only reflects the evolving expectations of patients seeking more effective and convenient treatments but also indicates a significant opportunity for innovative companies to leverage technology in delivering bespoke care in the diabetes sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Regulatory Landscape
• Patent Analysis
• PESTEL Analysis
• Pipeline Analysis
• Pricing Analysis

Type 2 Diabetes Market, by Drug Class

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like peptide 1 receptor agonists
• Biguanides
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors
• Others

Type 2 Diabetes Market, by Route of Administration

• Market Overview
• Oral
• Parenteral

Type 2 Diabetes Market, by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Type 2 Diabetes Market, by End User

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Type 2 Diabetes Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments